{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:59:37Z","timestamp":1793224777423,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"am","delay-in-days":266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152052","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T03:58:01Z","timestamp":1655438281000},"page":"152052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center"],"prefix":"10.1016","volume":"56","author":[{"given":"Brian H.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Taherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marka A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochra","family":"Jandali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen D.","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-4655","authenticated-orcid":false,"given":"Brian","family":"Skaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152052_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0002","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/BOR.0000000000000113","article-title":"Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement","volume":"26","author":"Domsic","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0003","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0004","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0006","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9343(97)00023-5","article-title":"Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies","volume":"103","author":"Spencer-Green","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0007","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.114.3.801","article-title":"African-American race and antibodies to Topoisomerase I are associated with increased severity of scleroderma lung disease","volume":"114","author":"Greidinger","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0008","first-page":"2454","article-title":"Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis","volume":"28","author":"Jacobsen","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.amjmed.2004.04.031","article-title":"Mortality in systemic sclerosis: an international meta-analysis of individual patient data","volume":"118","author":"Ioannidis","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0010","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11398","article-title":"The effect of Anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis","author":"Jandali","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0013","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0014","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.3003910","article-title":"High titers of autoantibodies to Topoisomerase I (Scl-70) in sera from scleroderma patients","volume":"231","author":"Shero","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0015","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.83.14.5145","article-title":"Topoisomerase I identified by scleroderma 70 antisera: enrichment of Topoisomerase I at the centromere in mouse mitotic cells before anaphase","volume":"83","author":"Maul","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF00286991","article-title":"Scl 70 autoantibodies from scleroderma patients recognize a 95kDa protein identified as DNA Topoisomerase I","volume":"94","author":"Guldner","year":"1986","journal-title":"Chromosoma"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.1780230602","article-title":"Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome","volume":"23","author":"Tan","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0018","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/ard.48.12.992","article-title":"Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations","volume":"48","author":"Aeschlimann","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0019","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0090-1229(90)90114-6","article-title":"Autoantibodies to Topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay","volume":"57","author":"Hildebrandt","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/art.1780340111","article-title":"Prognostic significance of anticentromere antibodies and anti-Topoisomerase I antibodies in Raynaud's disease. A prospective study","volume":"34","author":"Weiner","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0021","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-1759(96)00200-1","article-title":"Counterimmunoelectrophoresis with serum prediffusion: an improved method for the detection and identification of antibodies against extractable nuclear and cytoplasmic antigens","volume":"201","author":"Walravens","year":"1997","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0022","first-page":"1054","article-title":"Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens","volume":"11","author":"Martins","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0023","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1196\/annals.1313.036","article-title":"Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens","volume":"1050","author":"Damoiseaux","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12026-014-8601-5","article-title":"Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus","volume":"61","author":"Bentow","year":"2015","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0025","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/clinchem\/46.10.1681","article-title":"Sensitivity and specificity of immunological methods for the detection of anti-Topoisomerase I (Scl70) autoantibodies: results of a multicenter study. The Italian society of laboratory medicine study group on the diagnosis of autoimmune diseases","volume":"46","author":"Bizzaro","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000971","article-title":"Performance of anti-Topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting","volume":"26","author":"Homer","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0027","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3899\/jrheum.180503","article-title":"Presence of antiTopoisomerase I antibody alone may not be sufficient for the diagnosis of systemic sclerosis","volume":"46","author":"Tebo","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152052_bib0028","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/1529-0131(199904)42:3<455::AID-ANR10>3.0.CO;2-3","article-title":"A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity","volume":"42","author":"Tan","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:45Z","timestamp":1758733725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"alternative-id":["S0049017222001032"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152052","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152052"}}